Tiered manufacturing of pharmaceuticals as a commercial determinant of health: Implications for medicine quality and equity
Open Access
- 3 June 2026
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (6) , e0006576
Abstract
Tiered manufacturing, the practice of adapting different levels of pharmaceutical production standards to low- and middle-income countries (LMICs) versus high-income countries, has not been investigated as a commercial determinant of health (CDoH), defined by the World Health Organization as a private sector activity affecting public health. This paper examines this practice and its implications for medicine quality, universal health coverage, and global health equity. Guided by the CDoH framework, we conducted semi-structured interviews with 31 mostly India-based experts in pharmaceutical development, manufacturing, procurement, and regulation between May and July 2025. Purposive sampling ensured variation in geography, organizational type, and role. Transcripts were coded deductively using CDoH domains and inductively for emergent themes. Respondents consistently described “tiered manufacturing” — using different production standards by market. Medicines for countries regulated by Stringent Regulatory Authorities (SRA) (now called WHO Listed Authorities (WLA)) adhere to international good manufacturing practices (GMP) through rigorous documentation, stability testing, impurity profiling, and advanced infrastructure. In contrast, products supplied to LMICs are often produced with uncertain GMP compliance, cheaper raw materials, weaker documentation, and less stringent oversight, leading to variable quality and shortened shelf life. Commercial drivers were key determinants. Proposed solutions include improved mechanisms to verify versions of products being received, reliance on WHO prequalification or WLA approvals, procurement conditionality and strengthened local regulatory and manufacturing capacity. Tiered manufacturing was widely perceived as a common practice among respondents. Recognition of this practice as a CDoH is essential to strengthen regulatory reliance and enforcement, procurement leverage, and sustainable capacity-building, ensuring quality medicines for all globally.Keywords
Funding Information
- Bill and Melinda Gates Foundation (INV-080990)
This publication has 24 references indexed in Scilit:
- Substandard anticancer medications in clinical care settings and private pharmacies in sub-Saharan Africa: a systematic pharmaceutical investigationThe Lancet Global Health, 2025
- Minimizing the risk of ethylene glycol and diethylene glycol poisoning in medications: A regulatory and pharmacopoeial responseRegulatory Toxicology and Pharmacology, 2024
- Achieving health for all requires action on the economic and commercial determinants of healthThe Lancet, 2023
- Defining and conceptualising the commercial determinants of healthThe Lancet, 2023
- Quality of oxytocin and tranexamic acid for the prevention and treatment of postpartum hemorrhage in Kenya, Nigeria, South Africa, and TanzaniaInternational Journal of Gynecology & Obstetrics, 2022
- Quality of medicines in resource-limited settings: need for ethical guidanceGlobal Bioethics, 2018
- The commercial determinants of healthThe Lancet Global Health, 2016
- Fine Chemicals2011
- Impact of poor-quality medicines in the ‘developing’ worldTrends in Pharmacological Sciences, 2010
- Scale and scope in drug development: unpacking the advantages of size in pharmaceutical researchJournal of Health Economics, 2001